Search
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalDenufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. A new drug application (NDA) was filed with the FDA in 2011, however, the seco...
Olesoxime
go.drugbank.com/drugs/DB05185InvestigationalOlesoxime is a cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of both in vitro and in vivo preclinical models. For example, it has demonstrated the ability to prevent neurodegenera...
KW-7158
go.drugbank.com/drugs/DB05498ExperimentalKW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity (involuntary abnormal contraction of...
cryopreserved human liver cells
go.drugbank.com/drugs/DB05852ExperimentalVesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration. The Company's technology is centered on the isolation, expansion, and cryopreservation of liver cells (human hepatocytes) obta...
Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalBy binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the
XP21279
go.drugbank.com/drugs/DB06319InvestigationalXP21279 is a prodrug of Levodopa, a dopamine precursor used in the management of Parkinson's disease. XP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinso...
Ticlatone
go.drugbank.com/drugs/DB13613ExperimentalCategories: Antifungals for Topical Use, Antifungals for Dermatological UseMDX-1379
go.drugbank.com/drugs/DB05329InvestigationalMDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalIt was developed by Novartis and was granted FDA approval on November 15, 2019.